A phase II study to assess the safety and efficacy of DBd combination therapy (Doxil/Caelyx) [doxorubicin HCl liposome injection], Velcade [bortezomib] and dexamethasone) for previously untreated multiple myeloma patients.

Trial Profile

A phase II study to assess the safety and efficacy of DBd combination therapy (Doxil/Caelyx) [doxorubicin HCl liposome injection], Velcade [bortezomib] and dexamethasone) for previously untreated multiple myeloma patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2009

At a glance

  • Drugs Bortezomib; Dexamethasone; Doxorubicin liposomal
  • Indications Graft-versus-host disease; Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Janssen Inc
  • Most Recent Events

    • 06 Oct 2009 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 17 Aug 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 07 Dec 2007 Results will be presented at the 49th annual meeting of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top